Relugolix is an orally active, nonpeptide small molecule that acts as an antagonist of the gonadotropin-releasing hormone (GnRH) receptor [1]. It is approved in several countries for the treatment of advanced prostate cancer, heavy menstrual bleeding associated with uterine fibroids, and endometriosis [1][2].
How does relugolix work?
Relugolix functions by blocking the GnRH receptor in the pituitary gland. This blockade reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In men, this leads to a decrease in testosterone production by the testes. In women, it suppresses estrogen and progesterone production by the ovaries [1].
What is relugolix approved for?
In the United States, relugolix is approved under the brand name Orgovyx for the treatment of adult patients with advanced prostate cancer [1]. It is also approved under the brand name Myfembree, in combination with estradiol and norethindrone acetate, for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women and for the management of moderate to severe pain associated with endometriosis in premenopausal women [2].
What are the side effects of relugolix?
Common side effects of relugolix can include hot flashes, fatigue, joint pain, and decreased libido in men. In women, side effects may include hot flashes, menorrhagia (heavy menstrual bleeding), ovarian cysts, headache, and breast pain [1][2].
When does relugolix patent exclusivity expire?
Patent exclusivity timelines for drugs can be complex and vary by region. Information on specific patent expiry dates for relugolix and related formulations can be found on DrugPatentWatch.com [3].
Who manufactures relugolix?
Relugolix is developed and marketed by Myovant Sciences, which is a subsidiary of Sumitomo Pharma [1][2].
What is the difference between relugolix and other GnRH treatments?
Unlike injectable GnRH agonists or antagonists, relugolix is taken orally, offering a different administration route [1]. This oral formulation may provide convenience for patients.
Are there clinical trials or data on relugolix?
Clinical trials have demonstrated the efficacy of relugolix in reducing testosterone levels in men with advanced prostate cancer and in reducing heavy menstrual bleeding and pain associated with uterine fibroids and endometriosis in women [1][2].
What are the risks associated with relugolix?
For men being treated for advanced prostate cancer, risks include potential cardiovascular events, although studies have shown a cardiovascular safety profile comparable to other GnRH treatments [1]. For women using Myfembree, risks include bone density loss and thromboembolic events due to the reduction in estrogen [2].
Can generic versions of relugolix be developed?
The development of generic versions of relugolix is dependent on patent expiry and regulatory approvals. Once patents expire, other pharmaceutical companies may seek to market generic alternatives.
---
Sources
1. https://drugpatentwatch.com/relugolix
2. https://drugpatentwatch.com/myfembree
3. https://drugpatentwatch.com/